(NASDAQ: SUPN) Supernus Pharmaceuticals's forecast annual revenue growth rate of 33.1% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 10.67%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.22%.
Supernus Pharmaceuticals's revenue in 2026 is $830,438,000.On average, 7 Wall Street analysts forecast SUPN's revenue for 2026 to be $52,518,337,516, with the lowest SUPN revenue forecast at $50,099,672,505, and the highest SUPN revenue forecast at $54,319,693,649. On average, 7 Wall Street analysts forecast SUPN's revenue for 2027 to be $88,062,424,695, with the lowest SUPN revenue forecast at $56,588,390,966, and the highest SUPN revenue forecast at $147,700,740,033.
In 2028, SUPN is forecast to generate $111,545,737,947 in revenue, with the lowest revenue forecast at $63,416,571,183 and the highest revenue forecast at $161,767,477,179.